Compare Novavax Inc (NVAX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs T-Mobile Us Inc — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while T-Mobile Us Inc trades at $148.3 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 101× Novavax Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and T-Mobile Us Inc for 84 Days on average.
| NVAX | TMUS | |
|---|---|---|
Market Cap | $1.82B | $183.76B |
Volume | 6,198,505 | 4,294,650 |
Sector | Health | Media |
52-Week High | $12.56 | $230.06 |
52-Week Low | $6.22 | $161.73 |
Typical Hold Time | 59 Days | 84 Days |
Enterprise Value | $1.39B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
T-Mobile (TMUS) is trading at $149.79, down 10.64% in the last session. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent technical indicators are mixed with a bearish moving average signal but neutral oscillators. The company announced a 15% dividend increase and is advancing AI-powered 5G network capabilities. Analyst consensus remains strongly bullish with 79.6% buy ratings and a $231.10 price target.
TMUS presents a compelling growth story with solid financials and strategic initiatives, though elevated debt levels and competitive pressures pose risks. The current price decline may offer an entry point given the significant upside to analyst targets, supported by consistent earnings beats and dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
